8. Pro-Dex Inc. (NASDAQ:PDEX)
Pro-Dex, Inc. (NASDAQ: PDEX) takes the No. 8 position as an overlooked but profitable medical-technology company that designs and manufactures powered surgical instruments, particularly specialized handpieces used in orthopedic procedures. These products operate in a highly regulated market where reliability, engineering expertise, and long-standing customer relationships can create meaningful barriers to competition.
For its fiscal third quarter ended March 31, 2026, Pro-Dex, Inc. (NASDAQ: PDEX) reported record quarterly sales of approximately $19.9 million, increasing 15% from $17.4 million a year earlier. Net income reached approximately $3.9 million, or $1.20 per diluted share, while nine-month revenue increased 16% to approximately $57.1 million. Investors should note that reported earnings benefited from realized investment gains associated with Monogram Technologies.
The company’s small valuation creates meaningful upside if surgical-instrument demand continues growing and customer diversification improves. However, dependence on a limited number of major customers, acquisition-integration expenses, margin fluctuations, and low trading liquidity remain substantial risks. Pro-Dex, Inc. (NASDAQ: PDEX) is a potentially undervalued micro-cap medical stock, but limit orders and modest position sizing are essential.
